Covestor LTD Amicus Therapeutics, Inc. Transaction History

Covestor LTD

$160 Million
Q4 2024

A detailed history of Covestor LTD transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Covestor LTD holds 4,325 shares of FOLD stock, worth $37,324. This represents 0.03% of its overall portfolio holdings.

Number of Shares

4,325

Previous 2,013 114.85%

Holding current value

$37,324

Previous $22,000 86.36%

% of portfolio

0.03%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$9.36 - $12.01 $21,640 - $27,767	2,312 Added 114.85%	4,325 $41,000
Q3 2024 Nov 01, 2024	BUY	$9.55 - $12.09 $9 - $12	1 Added 0.05%	2,013 $22,000
Q2 2024 Aug 09, 2024	SELL	$9.04 - $11.75 $13,795 - $17,930	-1,526 Reduced 43.13%	2,012 $20,000
Q1 2024 May 10, 2024	BUY	$11.43 - $14.24 $10,069 - $12,545	881 Added 33.16%	3,538 $42,000
Q4 2023 Feb 09, 2024	BUY	$9.97 - $14.52 $16,809 - $24,480	1,686 Added 173.64%	2,657 $38,000
Q3 2023 Nov 13, 2023	BUY	$11.78 - $13.86 $7,350 - $8,648	624 Added 179.83%	971 $12,000
Q2 2023 Aug 11, 2023	SELL	$10.72 - $13.3 $19,038 - $23,620	-1,776 Reduced 83.66%	347 $4,000
Q1 2023 May 15, 2023	BUY	$10.91 - $13.54 $22,921 - $28,447	2,101 Added 9550.0%	2,123 $24,000
Q4 2022 Feb 13, 2023	SELL	$9.89 - $12.7 $19,997 - $25,679	-2,022 Reduced 98.92%	22 $0
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $19,718 - $25,602	2,008 Added 5577.78%	2,044 $21,000
Q2 2022 Aug 10, 2022	SELL	$6.23 - $11.12 $62 - $111	-10 Reduced 21.74%	36 $0
Q1 2022 May 13, 2022	SELL	$7.89 - $12.48 $86 - $137	-11 Reduced 19.3%	46 $0
Q4 2021 Feb 10, 2022	BUY	$9.82 - $12.44 $559 - $709	57 New	57 $1,000

Others Institutions Holding FOLD

# of Institutions

312

Shares Held

311M

Call Options Held

467K

Put Options Held

515K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.42B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account